Goldman Sachs Reiterates Buy Rating on Kiniksa (KNSA)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. SBUX
9. SNDK
10. MA

Go back to Goldman Sachs Reiterates Buy Rating on Kiniksa (KNSA)

Kiniksa Pharmaceuticals (KNSA) Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

January 13, 2025 7:31 AM EST

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported preliminary unaudited fourth quarter and full year 2024 ARCALYST net product revenue and provided 2025 ARCALYST net product revenue guidance.

ARCALYST uptake in recurrent pericarditis continues to grow. As of the end of 2024, approximately 13% of the... More